Merrimack Pharmaceuticals — Investor Presentation (September 2013)
21 slides from Merrimack Pharmaceuticals's investor presentation, Sep 9, 2013
Slide 1: A Fully Integrated Cancer Company
A Fully Integrated Cancer Company. ^ September 2013
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financi
Slide 3: Investment Highlights
Investment Highlights Expertise in multispecific antibodies and targeted nanotherapeutics discovery/development Systems biology-based R&D leverages signaling networks expertise and high throughput computational biology to discover novel therapeutics Six compounds in the clinic and a broad preclinica
Slide 4: Oncology Pipeline
Candidate Design Target Trial(1) Preclinical Phase 1 Phase 2 Phase 3 MM-121 Monoclonal antibody ErbB3 P1 combo: 48% ORR 70% CBR MM-111 Bispecific antibody ErbB3 & ErbB2 P1 combo: 42% ORR 52% CBR MM-151 Oligoclonal antibody EGFR P1 mono: TBA MM-141 Bispecific tetravalent antibody IGF-1R & ErbB3 P1 mo
Slide 5: Systems Biology Approach to R&D
Systems Biology Approach to R&D Gene Protein Network Network dynamics govern cell decisions Discovery focused on entire signaling networks, not individual molecules, to increase precision Platform couples high throughput quantitative biology with computing to build predictive models of biological ne
Slide 6: Two Differentiated Drug Technologies
Two Differentiated Drug Technologies 6 MultispecificAb Antibody engineering capabilities Novel antibody designs: bispecific targeting two receptors on same cell tetravalent antibody oligoclonal antibody antibody targeted nano-carriers Targeted Nano-therapeutics A version of Antibody Drug Conjugates
Slide 7: MM-398 Second Line Pancreatic Cancer
MM-398 Second Line Pancreatic Cancer Single arm, MM-398 monotherapy (120 mg/m2 q3w) (data as of May 31, 2012) 12 months – OS 25% 6 months – OS 42% Note: Frontline gemcitabine 12 months – OS 18% 3 months – OS 75% Nanotherapeutic encapsulation of irinotecan Engineered for increased drug deposition, lo
Slide 8: MM-398 Increases the Amount of Active Drug Available at the Tumor Site
MM-398 Increases the Amount of Active Drug Available at the Tumor Site Compared to Other Encapsulated Agents In Vitro t1/2 (h) AUC∞(µg*h/ml) Taxol 7.24 5.85 Abraxane 11.42 4.59 MM-398: Sustained intra-tumor levels t1/2 (h) AUC∞(µg*h/ml) CPT-11 .27 6 MM-398 10.7 2134 Desai et al. (2006) Clin Cancer R
Slide 9: Phase 3 Pancreatic Study Design (NAPOLI-1)
Phase 3 Pancreatic Study Design N=405 patients MM-398 (80 mg/m2 q 2wk) + 5FU/LV 5FU/LV (5/FU 2400 mg/m2 IV over 46 hrs, q2wk + LV 200mg/m2, q2wk) MM-398 (120 mg/m2 q3wk) Trial designed to determine the efficacy and safety of MM-398 alone or in combination with 5FU/LV versus an infusion of 5FU/LV Stu
Slide 10: MM-398 Update
MM-398 Update 10 Achieved NAPOLI-1 enrollment target of 405 patients in August 2013 Expect top line data from study Q4 2013 or Q1 2014 Study overseen quarterly by independent Data Safety Monitoring Board (DSMB) DSMB’s primary mission is safety; also reviews event rates Has authority to recommend con
Slide 11: MM-121 Monoclonal Ab to ErbB3
MM-121 Monoclonal Ab to ErbB3 - plays central role in survival and resistance Co-opted by EGFR & ErbB2 Translational focus in clinical program testing pre-specified biomarkers for ErbB3 dependency Goal to stratify patients in next phase clinical studies Global partner: Sanofi MM-121 + paclitaxel Pha
Slide 12: MM-121 Translational Focus
MM-121 Translational Focus MM-121 In Vivo Stratification Clinical Hypothesis ErbB3 plays an important role in resistance across tumor types When ErbB3 is active, treatment with 121 provide clinical benefit Translational Strategy Trials designed to assess the activation & prevalence of ErbB3 signalin
Slide 13: MM-121 Update
Phase 2: ER/PR+ Breast Cancer Phase 2: NSCLC wtEGFR Phase 2: ER/PR+ Breast Cancer Phase 2: Ovarian Cancer Phase 2: Triple-negative Breast Cancer Line of Therapy Second line metastatic Second line (no prior EGFR therapy) Neo-adjuvant Second line metastatic Neo-adjuvant Regimen MM-121 + exemestane MM-
Slide 14: MM-111 HER2-3 Bispecific Ab
MM-111 HER2-3 bispecific Ab Engineered against hyperactive HER2/HER3/HRG trimer Superior signaling inhibitor to current agents in preclinical studies Global Phase 2 targeting traditional HER2 adaptation and “non-traditional” HER2 patients Diagnostic approach: Stratifying based on HER2 and other biom
Slide 15: MM-302 ErbB2 Ab Targeted Nanotherapeutic
MM-302 ErbB2 Ab targeted nanotherapeutic encapsulation of doxorubicin Engineered for local accumulation & retention (10x) and maximal potency/cell uptake Designed to address cardiotox issues of combinations Diagnostic approach: PET/MRI imaging with copper labeled molecule Wholly owned 15 * * * * * *
Slide 16: MM-151 Oligoclonal Antibody
MM-151 Oligoclonal antibody combination designed to fully inhibit EGFR Superior signal inhibition, ligand antagonism, and receptor down-regulation in preclinical studies ADCC/CDC (fully human IgG1’s) Targeting wtEGFR LC & CRC Diagnostic approach: biomarker assays testing levels of high vs low affini
Slide 17: Business Development Pipeline
Business Development 17 Pipeline Collaborations Robust platform provides opportunity for product licensing Considering multiple types of transactions Deals covering one or multiple products Deals with regional vs. global commercial players Preference to retain US/EU marketing rights Platform Collabo
Slide 18: Financial Summary
Financial Summary 18 Financials Cash runway into 2015 6/30/13 cash and investments: $62M Completed $154M financing in July 2013 $29M equity $125M convertible debt Decrease in cash and investments from Q1 to Q2 of $25M Shares outstanding: ~102M as of 8/31 Sanofi MM-121 Partnership Worldwide co-develo
Slide 19: Multiple Data Read Outs Expected Near Term
19 Multiple Data Read Outs Expected Near Term Top line data for four Phase 2 studies for MM-121 including biomarker sub-population Second line ER/PR+ breast cancer Second line ovarian cancer Second line wtEGFR non-small cell lung cancer Neo-adjuvant ER/PR+ breast cancer Phase 1 data for MM-302 Prese
Slide 20: Investment Highlights
Investment Highlights Expertise in multispecific antibodies and targeted nanotherapeutics discovery/development Systems biology-based R&D leverages signaling networks expertise and high throughput computational biology to discover novel therapeutics Six compounds in the clinic and a broad preclinica
Slide 21: A Fully Integrated Cancer Company
A Fully Integrated Cancer Company 21 Eight Candidate Oncology Pipeline 6 clinical programs w/ 20+ clinical indications 2 pre-IND programs and a robust discovery capability Developing companion diagnostics for all oncology products Two Differentiated Drug Technologies Multispecific antibodies Targete
Merrimack Pharmaceuticals — Investor Presentation (September 2013) on 6ix